Category Archives: Cf

ATLANTA--(BUSINESS WIRE)--

CF Real Estate Services is pleased to announce that Tom Lamberth has been named regional partner. In addition to leading operations in Texas and Louisiana for the growing multifamily real estate firm, Lamberth will also be growing the companys presence through select opportunities in the Southwest.

We are very excited to have Tom join CF Real Estate Services, said Byron Cocke, co-CEO. Tom is a high-caliber individual with a stellar track record of performance in both property management and investment. We are looking to continue that track record with our new partnership at CF Real Estate Services.

In his new role, Lamberth will leverage his extensive background to expand the companys platform in development, acquisitions and third party property management services in Texas, Louisiana and surrounding markets, and will lead a team of top real estate professionals in the companys new regional office in Dallas.

Prior to joining CF Real Estate Services, Lamberth served as vice president at UDR for 15 years, where he was responsible for development activities in Texas and other select markets, including Washington, D.C.; North Carolina; Florida; and Arizona. His experience in the Dallas-Fort Worth area includes the assemblage, entitlement and development of Vitruvian Park in Addison, a 125-acre, urban master-planned, mixed-use development that will have 6,000 units when completed. Lamberth also served as an area director for UDR, heading the operations of 12,000 homes in markets throughout the Southeast and Mid-Atlantic. Prior to his tenure with UDR, Lamberth held senior-level positions with Lincoln Property Company, where, as senior vice president, he co-directed the operations of 42,000 apartment homes in the eastern U.S.

Headquartered in Atlanta, GA, CF Real Estate Services is a vertically integrated multifamily real estate firm. With decades of multifamily industry experience, the team has evolved into a leading provider of multifamily services including property management, asset management, and consulting. CF Real Estate Services serves clients in 14 states. With expertise in affordable, conventional and student housing, CF Real Estate Services successfully manages various holdings in multiple arenas of real estate.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170420005167/en/

Read more here:

Lamberth Named Regional Partner for CF Real Estate Services - Yahoo Finance

Crowdfunding, as allowed by Reg CF (created by Title III of the JOBS Act) was designed to improve access to capital for smaller firms in need of funding while providing new investment opportunities for smaller investors. For too many years the little guy has been boxed out from access to capital and early stage investments, so the story goes.

Oceans of money flowed into hotbeds of startup centers like Silicon Valley or Alley, but if youre not located in those epicenters, youre our of luck. Sorry. And if you were not a hotshot investor, well good luck.

Reg CF launched in May of 2016 with a decent amount of fanfare and a fair amount of optimism. Finally, the internet was going to democratize access to capital. It was about time.

But in the ensuing months, did this, in fact, occur? Good question.

Several weeks back, there was a closed meeting that involved members of the Securities and Exchange Commission (SEC), representatives from the North American Securities Administrators Association (NASAA) and other crowdfunding participants including several prominent platforms. The meeting was not open to press so (as far as I am aware) all proceedings were rather hush-hush. But several participants have spoken with representatives from Crowdfund Insider sharing a more dystopic view of the emerging Reg CF ecosystem.

One informed individual told Crowdfund Insider the sentiment was that the wheels have fallen off of Reg CF crowdfunding as the exemption has not lived up to the hype.

And why would this be? The challenges have to do with the highly prescriptive nature of Reg CF. The rules, designed to protect investors, may be doing just the opposite as very high quality firms do not want to pay the associated costs nor file all of the mandated disclosures. Using Reg D is far simpler and economical.

These litany of complaints are issues that several members of Congress have attempted to address. Most prominently, Congressman Patrick McHenry, the tenacious policymaker who has always been looking out for the little guy.

Yet time and again, his efforts to improve upon the existing Reg CF rules have been cut short, stymied by a perplexing group of malcontents and disbelievers. McHenrys office did not participate in the NASAA / SEC powwow but that should not come as a surprise. Why would you invite someone who wants to fix what is broken?

Speaking with one individual with knowledge of the event, they explained;

The general consensus was that Reg CF was totally dysfunctional. The NASAA representatives were pushing the low quality of the [crowdfunding] deals. Market participants were pointing to the compliance costs and the challenges intrinsic to Reg CF. There was disagreement as to why the exemption was not being adopted more broadly.

This individual said that NASAA was firmly entrenched with the belief that Reg CF does not exempt them from state compliance, even though that was the intent of Congress. This person said NASAA hates it.

They [NASAA] absolutely want to keep control over [securities] issuance They would love to see it go away. They are happy with the current state of affairs.

The thesis is that NASAA, a special interest group, wants issuers to use intrastate crowdfunding exemptions instead of a federal exemptions. NASAA is attempting to push Reg CF into obscurity so that companies looking to raise capital are compelled to go directly to the state. This is a question of state authority, power and money. This is a story of politics. Unfortunately the early stage company gets lost in this equation. Steamrolled by parochial politics.

Interestingly, the same individual said the SEC was more open to supporting Reg CF. Apparently, the Commission has been relieved to see that no cascade of fraud has taken place and they WANT Reg CF to be successful, recognizing the importance of capital formation for smaller firms. The SEC may even be inclined to revisit the exemption and do what they can to fix it. There was an overall willingness in the room to see crowdfunding as viable.

In NASAAs defense, the insider described NASAAs leadership as not completely indicative of member support. Many state regulators are more supportive than NASAA executives recognizing that economic need should trump small-minded politics. No one wants to remove NASAAs ability to enforce anti-fraud laws. But creating an ecosystem where issuers must kiss the ring and pay the toll of 50 states just doesnt make sense.

While there may never be clearcut unanimity on what must be done to improve the Reg CF exemption, many industry participants believe McHenrys first Fix Crowdfunding Act covered most all of the bases. Still, crowdfunding platforms continue to use the exemption with a certain amount of success. In nearly a year, almost $24 million has been raised to support entrepreneurial firms. But still more could be done as that is just a drop in the bucket.

Speaking with Kendrick Nguyen, co-founder and CEO of Republic, a mission driven crowdfunding platform that did not participate in the NASAA/SEC gathering, Nguyen believes that education and broad based information is mainly to blame;

I am not certain the concerns about the industry traction should be blamed on the SEC. Much of it is about investor education. This is something that can be simple and effective but people are unaware of it.

That being said, Nguyen acknowledges that simple improvements could easily be made to boost SME utilization;

The $1 million cap is not worth it for tech companies. $5 million would be nice. Accounting requirements and the ongoing reporting is the toughest thing for us. Companies that are most attractive to investors do not want to share their financials.

So where do we go now?

There is a Congressional push to help SMEs gain better access to capital but hurdles remain. Most elected officials have never started a company nor had to make payroll so there is a formative gap as to what it really takes. Special interest groups continue to pound the drum of investor protection to buttress their own opinions minus any actual data proving out pure speculation. While solutions to improving the crowdfunding ecosystem may seem simple to small business advocates, in our nations capital, political reality just delivers more regulatory challenges.

.

View post:

Have the Wheels Fallen Off of Reg CF Crowdfunding? - Crowdfund Insider

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announces the presentation of new data from its Phase 1 CF-301 study at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) to be held on April 22-25, 2017 in Vienna, Austria.

ContraFect's lead compound, CF-301 is a first-in-class lysin which has demonstrated a rapid and potent ability to kill Staphylococcus aureus (Staph aureus) bacteria in vitro and in animal studies. CF-301 is currently in development for the treatment of bacteremia due to Staph aureus, including methicillin resistant strains (MRSA). Initial results from the Phase 1, first-in-human study of CF-301 in healthy volunteers, which were presented in a late breaker presentation at ECCMID 2016, showed CF-301 to be well-tolerated with no clinical adverse safety signals. This year, long term follow-up data from this Phase 1 trial will be presented at ECCMID. In addition, a newly developed methodology for testing the susceptibility of Staph aureus bacteria to CF-301 in clinical settings will be presented.

"We are pleased to return to ECCMID, where we will present additional six-month follow up results from the initial Phase 1 study which extend our understanding of the safety profile of CF-301 and the timeframe for the resolution of anti-drug antibodies. We are also presenting a new methodology for CF-301 susceptibility testing, which has been optimized for use in clinical testing laboratories and which will be used in our upcoming Phase 2 study," said Cara Cassino, M.D., EVP of Research and Development and Chief Medical Officer at ContraFect.

Presentation Details:

Presentation Title: Long-Term Immunology Follow-up Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of Intravenous Doses of CF-301 In Human Subjects Session Day & Time: Saturday, April 22, 2017, 3:30p - 4:30p CET (10:30a-11:30a ET) Abstract Number: 7121 Session Title: Phages and Phage Products

Presentation Title: Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301 Session Day & Time: Saturday, April 22, 2017, 08:45a - 3:30p CET (3:45a-10:30a ET) E-poster number: EV0038 Abstract Number: 6193 Session Title: Bacterial Susceptibility & Resistance

The abstracts can be accessed through the ECCMID website. Following the meeting, the presentation posters will be available on the ContraFect Corporation website.

Continue reading here:

ContraFect (CFRX) to Present New Data from CF-301 Study at ECCMID - StreetInsider.com

Seattle-based immunotherapeutics firm Alpine Immune Sciences has agreed to a merger with Nivalis Therapeutics, which has been evaluating potential strategic alternatives since January this year, after its lead cystic fibrosis (CF) drug cavosonstat failed Phase II evaluation.

The stock-based transaction to combine the firms will see Alpine merged with a wholly owned Nivalis subsidiary. The joint entity will retain the Alpine Immune Sciences name and will be owned 74% by Alpine shareholders, with Nivalis stockholders owning the remaining 26%, based on a Nivalis valuation of $50 million, which includes the latters projected cash pot of $44 million.

The merged Alpine Immune Sciences business is expected to start out with approximately $90 million in cash and cash equivalents and will focus on exploiting Alpines vIgD (variant immunoglobulin domain) platform to develop engineered immune system proteins against inflammatory and autoimmune disorders and cancer.

Alpines current executive chairman and CEO Mitchell H. Gold, M.D., will head the merged company as chairman and CEO, and an expanded board of directors will seat two Nivalis representatives.

Dr. Gold described the merger as a unique opportunity to accelerate the development of its immunotherapy platform. We look forward to building on our early success by taking multiple novel programs into the clinic to help patients with significant medical needs, he said in a statement.

Alpine was founded in 2015 to develop a pipeline of vIgD-engineered immunotherapeutics that target the immune synapse. The firm is also leveraging the vIgD technology through its TIP (transmembrane immunomodulatory protein) program, which aims to enhance engineered cellular therapies (ECTs), including chimeric antigen receptor (CAR) T-cell, T-cell receptor (TCR), and tumor infiltrating lymphocyte (TIL) therapeutics. In October 2015, the firm inked a potentially $535 million deal with Kite Pharma to develop two Transmembrane Immunomodulatory Protein (TIPTM) programs into CAR and TCR product candidates.

Nivalis confirmed in November 2016 that the S-nitrosoglutathione reductase (GSNOR) inhibitor cavosonstat had failed in its first Phase II study, and at the start of January the Colorado-based firm announced that it was reviewing potential strategic alternatives. The firms then president and CEO Jon Congleton and CMO David Rodman, M.D., stepped down later in January as part of a cost-cutting restructuring exercise through which the firm said it would lose 25 of its 30-strong workforce, including the two executives. Six weeks after the restructuring announcement, Nivalis reported that cavosonstat had failed in a second Phase II CF study.

Original post:

Failed CF Drug Firm Nivalis to Merge with Immunotherapeutics Specialist Alpine - Genetic Engineering & Biotechnology News

Real Madrid, powered by a hat-trick byCristiano Ronaldo, won 4-2 after extra time to progress to the UEFAChampions League semifinals on Tuesday.

FC Bayern Munich left the Santiago Bernabeu furious with referee Viktor Kassai and his team of assistants after being knocked out of the UEFAChampions League by Real Madrid C.F. on Tuesday.

Real Madrid won 4-2 after extra-time to advance with a 6-3 aggregate success but Cristiano Ronaldo was offside for two of his three goals and a harsh dismissal for Arturo Vidal left a fuming Bayern with 10 men.

Chile midfielder Vidal was shown a second yellow card by Kassai in the 84th minute for what appeared a clean challenge on Marco Asensio, tilting the game in Madrids favour as they entered extra-time trailing 2-1.

Read more | Cristiano Ronaldo urges Real Madrid fans: Stop whistling me!

Ronaldo scored the next goal in the 105th minute from a clear offside position, and then sent Madrid 3-2 up on the night when fractionally offside.

When they rob a game from you like that, its very tough. This error cant happen in the Champions League, said Vidal.

When it was 2-1 they got scared and the referee started putting on his show. We played with one less man at home and here, too. The referee put us out of the Champions League.

Read more | Perhaps they wont boo him anymore: Real Madrid coach Zidane backs Cristiano Ronaldo

There were other contentious decisions on the night, including Casemiro avoiding a red card for a late foul on Bayerns Arjen Robben when already booked and an offside against Robert Lewandowski in the second half when the Polish striker was well placed.

Its very harsh, two offside goals, the red card for Casemiro before mine, said Vidal.

The dressing room is very sad because we really wanted to go through but we have to keep improving and hope these things will not happen again.

Were very angry, a game with that much intensity cant be decided by the referee.

Read more | Atletico Madrid prove fairytale killers, end Leicester City F.C. run inChampions League

Bayern coach Carlo Ancelotti agreed with Vidal and said in his media conference that the referees needed video help.

Arturos card was not a card and then two goals for Cristiano were offside, said the Italian.

We are not happy about this. In a quarter-final you have to have a referee with more quality, I think. Its time to introduce videos for the referees.

His Real Madrid counterpart Zinedine Zidane did not want to discuss the refereeing but he claimed Bayerns second goal could have also been ruled offside.

Lewandowski appeared to be fractionally offside in the buildup to Sergio Ramoss own goal, causing panic in the area before the defender prodded the ball past Keylor Navas.

Read more | AFC Cup: Mohun Bagan may start with all-Indian 11 against Maldives Maziya

They have told me their second goal was also offside. It goes both ways, that is football, said Zidane.

More than the second yellow (for Vidal) or the offside goals, the six goals we scored over the two games mean we deserved to go through in the tie.

View original post here:

FC Bayern Munich fume over Champions League 'robbery' by Real Madrid CF - Hindustan Times

NY Stock News

The Technicals For CF Industries Holdings, Inc. (CF) Tell An Interesting Tale NY Stock News The technicals for CF Industries Holdings, Inc. (CF) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. The technical data for a stock offers a rich ... and more »

Read more:

The Technicals For CF Industries Holdings, Inc. (CF) Tell An Interesting Tale - NY Stock News

The local chapter of Cystic Fibrosis Canada invites Sudbury residents to the Walk to Make Cystic Fibrosis History at Kivi Park on Sunday, May 28.

Sudburians will join thousands of Canadians on this day as they participate in community walks across the country to celebrate fundraising efforts and support Cystic Fibrosis Canadas mission to end cystic fibrosis. Money raised goes to world-class research and to advocate and support high-quality individualized CF care.

This is the first year the walk will take place at Kivi Park, 4472 Long Lake Rd., and organizers are aiming to increase participation and awareness surrounding this fatal disease that affects children, adolescents and adults.

Kivi Park has more than 300 acres of space, which makes it the ideal location for us, Chantal Filion, president of the local chapter, said. There is more than enough space to accommodate our CF community and supporters, as well as abide by the infection control policy.

People living with CF are at greater risk of getting lung infections than those who dont have the disease. For this reason people living with CF must keep a distance of six feet from each other at all times.

In Canada, it is estimated that one in every 3,600 children born has CF, a disease that has various effects on the body, but mainly on the digestive system and lungs. Currently, there is no cure.

This is the reality for more than 4,100 Canadians who attend specialized CF clinics and the reality for the Filion family in Sudbury.

Filions sister, Megan, is the treasurer of the Sudbury chapter. The sisters have organized the Walk since 2014, during which time they have raised more than $52,000.

Megans daughter, Janessa, was diagnosed with CF at the age of one.

These local fundraising efforts will benefit my family and provide funds for research and care to others who live with CF across Canada, Megan said. Hopefully one day we will find a cure so my daughter and others affected can live a long and healthy life with less worry.

Janessa is 15 now and follows a strict daily routine in order to stay healthy. To keep her lungs clear, airway clearance techniques are administered a few times a day for 20-30 minutes at a time. Janessa must take many medications to ensure her digestive system remains healthy, too. Janessa is in Grade 9 and fortunately is able to attend high school. She visits the CF clinic at Health Sciences North every three months.

Participants will enjoy full use of Kivi Park, although the 3.5 km Green Trail, also known as the Wishing Tree Trail, will be dedicated to the walk.

We are excited to be able to support groups like Cystic Fibrosis Canada and their effort to raise money and awareness about our countrys most common fatal genetic disease, Melissa Sheridan, park leader, said.

The Sudbury Cystic Fibrosis clinic in NEO Kids at Health Sciences North is the only CF clinic in Northern Ontario, attracting patients from as far as Timmins, Sault Ste Marie, Temiskaming and Parry Sound.

According to the Canadian Cystic Fibrosis Registry, there are 30 children and 43 adults that attend the clinic in Sudbury.

Catherine Watsons two children, Braeden, 14, and Parker, 8, both live with CF.

Both boys are extremely active in most sports, which can make it that much more difficult for them to cope when not feeling well, she said. They often push through how they are feeling in order to remain active and accomplish what they have set out to do. They are determined not to let cystic fibrosis define the way they live.

The Watson family has attended every CF Walk in Sudbury over the past six years.

Walk day is an emotional day for me especially when you see the large groups of family and friends making their way to the start line, Watson said. The walk is a reminder that we are not alone while dealing with a disease that can be very isolating at times.

The walk takes place from 10 a.m. to 2 p.m. Registration is at 10 a.m. and the walk begins at 11 a.m. Food and entertainment will follow. To register for the May 28 walk, visit cysticfibrosis.ca/walk.

Sud.editorial@sunmedia.ca

View original post here:

Kivi Park hosts annual CF walk - The Sudbury Star

SERGEANT BLUFF Greg Kennette only took three days off of work last year, one of which was to witness the birth of his son.

Kennette is the commissioning superintendent for CF Industries. His previous around-the-clock work schedule is similar to the experience of just about everyone who had a hand in building or developing thenitrogen-based fertilizer manufacturer's$2 billion expansion to its Port Neal complex south of Sioux City.

That was everybody, said Nick DeRoos when told about Kennette's schedule. We were out here starting up in the middle of winter, right? Christmas was out here for a lot of people and thats something. The commitment of the people involved in this was just extraordinary.

DeRoos is the general manager of the CF Port Neal complex and served as the project director of the expansion, which at one time was the largest single private capital investment in Iowa history.

Ground broke on the mega expansion in fall 2013 and it required more than 5,300 construction workers to complete. Crews erected 33 new buildings, built a temporary jetty on the Missouri River and added 8.5 miles of rail line over a 350-acre site, which occupies a little more than three times the acreage of CFs original plant south of the expansion.

Some of the most prominent additions are a new administration building, a state-of-the-art shipping and weighing center for trucks, a new ammonia plant, a new granular urea plant and a third-of-a-mile-long granular urea warehouse, which CF officials noted is one of the largest facilities of its type in North America.

The new plants became operational late last year and expand the regional production capabilities of CF, which is based in Deerfield, Illinois.

The ammonia plant, which began production in late November, has operated at about its nameplate capacity of 2,425 tons per day, while the front end of the plant produces carbon dioxide used to manufacture urea in an adjacent plant.

With the additional facilities operations, total annual gross ammonia capacity at the CF complex is now 1.2 million tons, more than triple the 380,000 tons previously. Output from the new ammonia plant will largely be upgraded to urea, and total annual urea capacity at Port Neal is now 1.4 million tons, up from 50,000 tons previously.

DeRoos is excited about the additions and noted his crew is starting to adjust to operating the new facilities.

The guys are getting more accustomed to operating an operating plant versus still starting up the startup is unique, but they want to be operating, he said. They want the plant up, making product, lined out and basically predictable, reliable operations and thats where we're at today.

While CFs large-scale investment in itself is expected to aid the business, it also proved to be a major economic boon for the region during and after construction.

We worked with planning group, Woodbury County and a number of regional municipalities just anticipating that there were going to be some impacts, but the impact was more than we could have imagined at the time, DeRoos said. We didnt fully appreciate the scale of the project that we were doing until we got farther along.

Thousands of the construction workers came from out of state, and DeRoos noted that the taxes collected from the contractors plus the money they spent while here is almost unquantifiablebut significant.

It was good for the whole area; businesses thrived, he said. Our suppliers, we had all kinds of people, businesses in the area helping supply either directly or indirectly the materials and products and even services for the plant.

CF worked with more than 100 local vendors during the expansion and at least 700 local indirect jobs were created to support the endeavor. DeRoos said it was great to see the region come together to complete something this large.

It gave this whole area a great manufacturing facility for years to come, he said.

Additionally, CF brought on 125 new full-time employees to man its upgraded operations, increasing the total workforce of the complex to 270.

The majority of those people are local and they came from all walks of life teachers, accountants, car salesman all kinds of people joined us, DeRoos said of the new hires. The jobs that we are offering are very high-paying jobs.

With one major undertaken complete, CF plans to upgrade the ammonia converter system at its original nitrogen production plant over the next couple of years.

This project will cost about $25 million and require about 500 contractors to complete. Additionally, components of the upgrade are being shipped from Italy and will be barged to the site via the Missouri River this spring.

DeRoos noted its pretty standard for CF to upgrade equipment every couple of years and predicts that within the next decade a turnaround a process where a facility is completely shut down for maintenance activities will be required for the new plants.

However, with the newer project still a few months away, DeRoos still takes solace in the completion of CFs recent 10-digit undertaking.

Were glad its behind us, DeRoos joked. Were thrilled to be making product."

See more here:

PROGRESS: CF Industries officials glad to be done with major expansion - Sioux City Journal

CF Industries Holdings, Inc. (CF)

Goldman Sachs Upgrades CF Industries Holdings, Inc. (CF)s stock to Buy with no specific Price Target. This rating was issued on 3/20/17. The stock recently closed its previous session at $28.42 by showing a percentage change of -0.7% from its previous day closing price of $28.62.

Price Target is basically a projection of future price of a companys stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on CF Industries Holdings, Inc. (CF) in which Cowen & Co. Upgrades CF Industries Holdings, Inc. (CF) to Market Perform with no specific Price Target on 1/24/17. UBS Downgrades the stock to Neutral on 1/10/17 by stationing a price target of $35. Barclays Downgrades the companys stock to Equal-Weight on 12/12/16 with no specific Price Target. RBC Capital Downgrades CF Industries Holdings, Inc. (CF) to Underperform with no specific Price Target.

CF Industries Holdings, Inc. (CF) currently has a consensus Price Target of $32.24. While some analysts have a High Price target for the stock of $42 and a Low Price Target of $24.

Several sell side analysts reviewed their recommendations on CF Industries Holdings, Inc. (CF) where 1 analyst have rated the stock as Strong Buy, 5 analysts said its a Buy, 10 rated the stock as Hold, 1 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 3. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, CF Industries Holdings, Inc. (CF) reported its Actual EPS of $-0.39/share. The analysts offering Earnings Estimates for the company were believing that CF Industries Holdings, Inc. (CF) could bring EPS of $-0.05/share. The difference between Actual EPS and Estimated EPS was -0.34 Percent. Thus the company showed an Earnings Surprise of -680 Percent.

CF Industries Holdings, Inc. (CF) has a market capitalization of 6.63 Billion. The stock traded with the volume of 2.7 Million shares in the last trading session. The stock touched its high share price of $36.86 on 01/25/17 and the stock also touched its Lowest price in the last 52-weeks of trading on 08/04/16 as $20.08. The company has a 1 Year high price target of $32.94. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -3.47%. The Moving Average SMA50 is -9.41% while SMA200 is 3.11%.

CF Industries Holdings, Inc. (CF) is currently showing its ROA (Return on Assets) of -1.8%. The Return on Investment (ROI) is at 0.4% while its Return on Equity (ROE) value stands at -7.3%. The stock currently shows its YTD (Year to Date) performance of -8.97 percent while its Weekly performance value is -4.18%. The Monthly and Yearly performances are -1.49 percent and -2.96 percent respectively. The Relative Volume value measured for CF Industries Holdings, Inc. (CF) is 0.52. The Average Volume (3 months) is 5.22 Million.

The stock currently has its Annual Dividend of $1.2 and an annual Dividend Yield of 4.22 Percent. CF has P/E (Price to Earnings ttm) value of 0, Forward P/E of 28.19, P/C (Price to cash per share) of 0 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of -0.9 percent.

Company Profile:

CF Industries Holdings, Inc. is the holding company for the operations of CF Industries, Inc. CF Industries, Inc. is a major producer and distributor of nitrogen and phosphate fertilizer products. CF Industries operates world-scale nitrogen fertilizer plants in Louisiana and Alberta, Canada; conducts phosphate mining and manufacturing operations in Central Florida; and distributes fertilizer products through a system of terminals, warehouses, and associated transportation equipment located primarily in the midwestern United States.

Read this article:

Stock Showing Surging Activity: CF Industries Holdings, Inc. (CF) - HugoPress

Gareth Bale has been ruled out for Real Madrid C.F.s match against Sporting Gijon due to injury while Cristiano Ronaldo has been rested as he prepares for the Champions League.

Gareth Bale will miss Real Madrids trip to Sporting Gijon on Saturday and faces a race against time to be fit for Reals Champions League quarter-final second leg against Bayern Munich on Tuesday.

Bale had to be replaced for the final half hour of Madrids 2-1 win in Munich on Wednesday after aggravating an ankle injury that saw him miss nearly three months earlier this season.

The Welshman is just one of seven first team regulars not included in Zinedine Zidanes squad with Cristiano Ronaldo and Karim Benzema also rested.

He will not be with us tomorrow, that is clear, after that we will see, Zidane said on Friday. It is a muscular problem, it is where he had his operation. When he started to play again it has bothered him. It is true that I am concerned. I dont like to see my players injured and even more so in the final straight of the season.

As in recent away games at Eibar and Leganes, Zidane is backing the strength in depth of his squad to get the job done with the second leg against Bayern in mind.

Goalkeeper Keylor Navas is also rested, whilst Dani Carvajal is suspended and central defensive duo Pepe and Raphael Varane miss out due to injury.

Real have made a positive start to a huge April with Barcelona also visiting the Santiago Bernabeu next weekend.

Zidanes men have opened up a three-point lead over Barca at the top of the table and have a game still in hand.

Meanwhile, they remain on course to become the first team to retain the Champions League in 27 years.

I think it is the DNA of this club, the more difficult the matches, the more the players respond, added Zidane. We are all happy when the end of the season arrives with important matches.

Continued here:

Cristiano Ronaldo rested, Gareth Bale out for Real Madrid CF in La Liga clash - Hindustan Times